Related Experiment Videos
Azithromycin in lower respiratory tract infections
1Department of Chest and Infectious Diseases, City Hospital Zehlendorf Heckeshorn, Berlin, Germany.
Scandinavian Journal of Infectious Diseases. Supplementum
|January 1, 1992
Summary
Azithromycin, an azalide antimicrobial, effectively treats lower respiratory tract infections. Short-course azithromycin therapy offers comparable efficacy to longer antibiotic courses, improving patient compliance.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Azithromycin is a novel azalide antimicrobial agent.
- It exhibits broad-spectrum activity against common respiratory pathogens.
- Demonstrates superior activity against Haemophilus influenzae compared to other macrolides.
Purpose of the Study:
- To evaluate the efficacy and pharmacokinetic profile of azithromycin.
- To compare short-course azithromycin therapy with standard antibiotic treatments for lower respiratory tract infections.
Main Methods:
- Clinical studies were conducted to assess azithromycin's efficacy.
- Pharmacokinetic parameters including tissue and intracellular concentrations were measured.
- Comparative analysis with amoxicillin/clavulanic acid, erythromycin, and cefaclor was performed.
Main Results:
- Azithromycin achieves high and sustained tissue and intracellular concentrations.
- A 3- or 5-day azithromycin course was as effective as a 10-day course of other antibiotics.
- Efficacy was demonstrated against key lower respiratory tract pathogens.
Conclusions:
- Azithromycin is an effective treatment for lower respiratory tract infections.
- Short-course azithromycin therapy enhances patient compliance and reduces treatment duration.
- Its pharmacokinetic profile supports once-daily dosing and sustained antimicrobial activity.